KU-32, a Novel Drug for Diabetic Neuropathy, Is Safe for Human Islets and Improves In Vitro Insulin Secretion and Viability
Figure 7
KU-32 improved the total islet area, but not the islet density or cell composition. (a) Treatment with KU-32 increased the total area of the pancreas identified by immunohistochemistry as endocrine cells. (*indicates , islet from vehicle-treated mice, and 46 islets from KU-32 treated mice). (b) KU-32 decreased the density of islets per pancreatic section analyzed. (*indicates , n = analysis of 4 sections from 3 vehicle-treated mice and 6 sections from 3 KU-32-treated mice). (c) There was no difference in the percentage of α, β, or δ cells in each islet analyzed. ( islets from vehicle-treated mice and 40 islets from KU-32 treated mice).
